As we begin to reopen Rush University Medical Center for elective procedures and in-person care, we are putting your safety first. For information about COVID-19, see the latest updates. Rush accepts donations to support our response effort, staff, and patients and families.
Renal Cell Carcinoma Treatment Study
To provide combination therapies in treatment for patients with advanced renal cell carcinoma and to collect additional data on treatment safety.
In order to participate you must meet the following criteria:
- Have advanced (not amenable to curative surgery or radiation treatment) or metastatic (American Joint Committee on Cancer Stage IV) renal cell carcinoma.
- Have a histological confirmation of renal cell carcinoma with a clear-cell component.
- Can be anti-PD-1, anti-PD-L1, or anti-CTLA-4 naïve or experienced.
- Have at least 1 lesion with measurable disease.
You will be excluded from the study if any of the following criteria apply to you:
- Have suspected, known, or progressive CNS metastases; have untreated CNS metastases; or have the CNS as the only site of disease.
- Have received any anti-cancer treatment (eg, chemotherapy, radiotherapy [except for palliative radiotherapy, which can be received up to 2 weeks prior to study treatment]; biologics; or immunotherapies, including investigational treatments) within 4 weeks prior to the first dose of study treatment.
- Have active, known, or suspected autoimmune disease.
- Have uncontrolled or significant cardiovascular disease.
This is a partial list of inclusion and exclusion criteria.